JP4115517B2 - 白血球付着分子 ｖｌａ−４に対するヒト化抗体 - Google Patents

白血球付着分子 ｖｌａ−４に対するヒト化抗体 Download PDF

Info

Publication number
JP4115517B2
JP4115517B2 JP51977095A JP51977095A JP4115517B2 JP 4115517 B2 JP4115517 B2 JP 4115517B2 JP 51977095 A JP51977095 A JP 51977095A JP 51977095 A JP51977095 A JP 51977095A JP 4115517 B2 JP4115517 B2 JP 4115517B2
Authority
JP
Japan
Prior art keywords
humanized
seq
sequence
variable region
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP51977095A
Other languages
English (en)
Japanese (ja)
Other versions
JPH09508272A (ja
Inventor
エム． ベディング，メアリー
ジェイ． レジェ，オリビエ
サルダンハ，ジョゼ
エス． ジョーンズ，タラン
Original Assignee
エラン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エラン ファーマシューティカルズ， インコーポレイテッド filed Critical エラン ファーマシューティカルズ， インコーポレイテッド
Publication of JPH09508272A publication Critical patent/JPH09508272A/ja
Application granted granted Critical
Publication of JP4115517B2 publication Critical patent/JP4115517B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP51977095A 1994-01-25 1995-01-25 白血球付着分子 ｖｌａ−４に対するヒト化抗体 Expired - Lifetime JP4115517B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
US08/186,269 1994-01-25
PCT/US1995/001219 WO1995019790A1 (en) 1994-01-25 1995-01-25 Humanized antibodies against leukocyte adhesion molecule vla-4

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2005228930A Division JP2006045237A (ja) 1994-01-25 2005-08-05 白血球付着分子ｖｌａ−４に対するヒト化抗体

Publications (2)

Publication Number Publication Date
JPH09508272A JPH09508272A (ja) 1997-08-26
JP4115517B2 true JP4115517B2 (ja) 2008-07-09

Family

ID=22684288

Family Applications (5)

Application Number Title Priority Date Filing Date
JP51977095A Expired - Lifetime JP4115517B2 (ja) 1994-01-25 1995-01-25 白血球付着分子 ｖｌａ−４に対するヒト化抗体
JP2005228930A Withdrawn JP2006045237A (ja) 1994-01-25 2005-08-05 白血球付着分子ｖｌａ−４に対するヒト化抗体
JP2009120421A Withdrawn JP2009235078A (ja) 1994-01-25 2009-05-18 白血球付着分子ｖｌａ−４に対するヒト化抗体
JP2013028635A Expired - Lifetime JP5487382B2 (ja) 1994-01-25 2013-02-18 白血球付着分子ｖｌａ−４に対するヒト化抗体
JP2013054628A Withdrawn JP2013165718A (ja) 1994-01-25 2013-03-18 白血球付着分子ｖｌａ−４に対するヒト化抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2005228930A Withdrawn JP2006045237A (ja) 1994-01-25 2005-08-05 白血球付着分子ｖｌａ−４に対するヒト化抗体
JP2009120421A Withdrawn JP2009235078A (ja) 1994-01-25 2009-05-18 白血球付着分子ｖｌａ−４に対するヒト化抗体
JP2013028635A Expired - Lifetime JP5487382B2 (ja) 1994-01-25 2013-02-18 白血球付着分子ｖｌａ−４に対するヒト化抗体
JP2013054628A Withdrawn JP2013165718A (ja) 1994-01-25 2013-03-18 白血球付着分子ｖｌａ−４に対するヒト化抗体

Country Status (21)

Country Link
EP (2) EP0804237B8 (enExample)
JP (5) JP4115517B2 (enExample)
KR (1) KR100367948B1 (enExample)
CN (1) CN1211123C (enExample)
AT (1) ATE333895T1 (enExample)
AU (1) AU703152B2 (enExample)
CA (1) CA2182013C (enExample)
DE (2) DE122006000043I1 (enExample)
DK (2) DK0804237T3 (enExample)
ES (2) ES2424292T3 (enExample)
FI (1) FI117509B (enExample)
FR (1) FR06C0024I2 (enExample)
HU (1) HU220799B1 (enExample)
LU (1) LU91271I2 (enExample)
MX (1) MX9602971A (enExample)
NL (1) NL300238I2 (enExample)
NO (3) NO319867B1 (enExample)
NZ (1) NZ279730A (enExample)
PL (1) PL181827B1 (enExample)
PT (1) PT804237E (enExample)
WO (1) WO1995019790A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) * 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO2000015247A2 (en) * 1998-09-14 2000-03-23 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
IL145898A0 (en) * 1999-04-22 2002-07-25 Biogen Inc Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
EE200100651A (et) 1999-06-01 2003-02-17 Biogen, Inc. VLA-1 blokeeriv monoklonaalne antikeha ja tema kasutamine põletiku raviks
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
DK2140881T3 (da) * 1999-12-16 2013-05-06 Biogen Idec Inc Fremgangsmåder til behandling af iskæmisk eller hæmoragisk læsion i centralnervesystemet ved anvendelse af anti-alpha-4-integrin-antagonister
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
NZ529494A (en) 2001-04-13 2005-08-26 Biogen Idec Inc Antibodies to VLA-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
NZ535320A (en) 2002-02-25 2008-05-30 Elan Pharm Inc Administration of agents that bind to an alpha-4 integrin for the treatment of inflammation
CA2481747A1 (en) * 2002-04-12 2003-10-23 Medimmune, Inc. Recombinant anti-interleukin-9 antibodies
GB0210121D0 (en) * 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
AR040778A1 (es) * 2002-08-06 2005-04-20 Glaxo Group Ltd Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina).
AU2003298187B2 (en) * 2002-12-17 2010-09-16 Merck Patent Gmbh Humanized antibody (H14.18) of the mouse 14.18 antibody binding to GD2 and its fusion with IL-2
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
WO2005061466A1 (ja) 2003-12-22 2005-07-07 Ajinomoto Co., Inc. 新規フェニルアラニン誘導体
CN103169965A (zh) * 2004-11-19 2013-06-26 比奥根艾迪克Ma公司 治疗多发性硬化
WO2007061679A1 (en) * 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
CN105381459A (zh) 2006-05-25 2016-03-09 比奥根Ma公司 治疗中风的方法
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
US20080311119A1 (en) * 2007-06-14 2008-12-18 Biogen Idec Ma Inc. Antibody formulations
BRPI0820202B1 (pt) 2007-12-13 2018-05-08 Tokuyama Corp composição curável fotocrômica
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
MY162752A (en) 2009-03-20 2017-07-14 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
ME02793B (me) 2010-04-16 2018-01-20 Biogen Ma Inc Anti-vla-4 antitijela
CA2834900C (en) 2011-05-02 2021-03-02 Millennium Pharmaceuticals, Inc. Formulation for anti-.alpha.4.beta.7 antibody
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
US20190374639A1 (en) 2016-11-21 2019-12-12 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126B1 (en) * 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
WO2018224673A1 (en) 2017-06-08 2018-12-13 Zaklady Farmaceutyczne Polpharma S.A. Improved methods of cell culture
EP3800999A4 (en) 2018-06-04 2022-06-01 Biogen MA Inc. ANTI-VLA-4 ANTIBODY WITH REDUCED EFFECTIVE FUNCTION
WO2022162164A1 (en) 2021-01-29 2022-08-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
IL113261A (en) * 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
DK0625912T3 (da) * 1992-02-12 1997-10-27 Biogen Inc Behandling af inflammatorisk tarmsygdom
AU688751B2 (en) * 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Also Published As

Publication number Publication date
PL181827B1 (pl) 2001-09-28
AU1696095A (en) 1995-08-08
JPH09508272A (ja) 1997-08-26
NO963097D0 (no) 1996-07-24
JP2009235078A (ja) 2009-10-15
JP5487382B2 (ja) 2014-05-07
ES2424292T3 (es) 2013-09-30
NZ279730A (en) 1998-04-27
NO2006008I1 (no) 2006-08-07
DE69535133T2 (de) 2008-08-21
KR970700513A (ko) 1997-02-12
MX9602971A (es) 1998-01-31
ATE333895T1 (de) 2006-08-15
NO319867B1 (no) 2005-09-26
EP0804237A1 (en) 1997-11-05
FI117509B (fi) 2006-11-15
HU9602019D0 (en) 1996-09-30
NO963097L (no) 1996-09-24
HUT75129A (en) 1997-04-28
DK1759709T3 (da) 2013-06-10
FI962958L (fi) 1996-09-24
DK0804237T3 (da) 2006-10-16
EP0804237B8 (en) 2006-11-08
EP1759709B1 (en) 2013-02-27
NO2017040I1 (no) 2017-08-01
DE69535133D1 (de) 2006-09-07
FR06C0024I2 (fr) 2009-01-02
AU703152B2 (en) 1999-03-18
CA2182013A1 (en) 1995-07-27
WO1995019790A1 (en) 1995-07-27
CN1211123C (zh) 2005-07-20
PT804237E (pt) 2006-10-31
EP0804237A4 (en) 2003-04-16
KR100367948B1 (ko) 2003-07-12
JP2013173738A (ja) 2013-09-05
NL300238I1 (enExample) 2006-10-02
ES2270425T3 (es) 2007-04-01
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
NO2006008I2 (no) 2009-06-15
EP1759709A1 (en) 2007-03-07
LU91271I2 (fr) 2006-10-02
NO2017040I2 (no) 2018-08-28
JP2006045237A (ja) 2006-02-16
CA2182013C (en) 2007-07-17
EP0804237B1 (en) 2006-07-26
NL300238I2 (nl) 2007-05-01
PL315634A1 (en) 1996-11-25
JP2013165718A (ja) 2013-08-29
DE122006000043I1 (de) 2007-02-15
HU220799B1 (hu) 2002-05-28
FR06C0024I1 (enExample) 2006-10-13

Similar Documents

Publication Publication Date Title
JP4115517B2 (ja) 白血球付着分子 ｖｌａ−４に対するヒト化抗体
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
US6204007B1 (en) Antibodies against E-selectin
EP2254911B1 (en) Humanized anti-c5ar antibodies
US6590079B2 (en) Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
EP0678122B1 (en) Recombinant anti-vla4 antibody molecules
SK16762000A3 (sk) Protilátky proti cd23, farmaceutický prostriedok s ich obsahom, sekvencie dna kódujúce reťazec protilátok a použitie protilátok
EP0968290B1 (en) Anti-alphavbeta3 humanized monoclonal antibodies
WO1998040488A9 (en) Anti-alphabeta3 humanized monoclonal antibodies
CN114269788B (zh) 一种能够与人4-1bb结合的分子及其应用
HK1011031B (en) Recombinant anti-vla4 antibody molecules

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20040511

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20040811

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20040927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041110

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20041110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20041110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20050509

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20050627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050805

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20050920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20070904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071203

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080208

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080416

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4115517

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140425

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D13

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term